Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4

Cancer Research

Volumn 71, Issue 24, 2011, Pages 7410-7422

  Wang, Xinhui ^a,b   Katayama, Akihiro ^a,b,d   Wang, Yangyang ^a,b   Yu, Ling ^a,b   Favoino, Elvira ^a,b   Sakakura, Koichi ^a,b   Favole, Alessandra ^a,b   Tsuchikawa, Takahiro ^a,b   Silver, Susan ^c   Watkins, Simon C ^b   Kageshita, Toshiro ^a,b   Ferrone, Soldano ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Special Pathogens Laboratory   (United States)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEOCHONDROITIN SULFATE; PROTEOCHONDROITIN SULFATE 4; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA; CELL GROWTH; CELL MIGRATION; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; LUNG METASTASIS; MELANOMA CELL; MESOTHELIOMA; MOLECULAR RECOGNITION; MOUSE; MYELOID LEUKEMIA; NEUROECTODERM TUMOR; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITOPES; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOTHERAPY; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEOGLYCANS; SINGLE-CHAIN ANTIBODIES; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84255192093     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1134     Document Type: Article

References (47)

1. Campoli M, Ferrone S. Immunotherapy of malignant disease: the coming age of therapeutic monoclonal antibodies. In: DeVita V, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. New York: Lippincott Williams & Wilkins; 2009. p. 1-18.
2. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, et al. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 2004;165:881-91. (Pubitemid 38821978)
3. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, et al. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res 2009;69:7538-47.
4. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, et al. CSPG4 in cancer: multiple roles. Curr Mol Med 2010;10:419-29.
5. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004;24:267-96. (Pubitemid 40052428)
6. Mittelman A, Chen ZJ, Kageshita T, Yang H, Yamada M, Baskind P, et al. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990;86:2136-44.
7. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A 1992;89:466-70.
8. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 1994;54:415-21.
9. Mittelman A, Chen GZ, WongGY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1995;1:705-13.
10. Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, et al. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 2005;114:426-32. (Pubitemid 40279964)
11. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, et al. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst 2010;102:1496-512.
12. Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV. SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. Mol Immunol 2004;41:863-72. (Pubitemid 38903170)
13. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006;58:640-56. (Pubitemid 44262411)
14. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
15. Schwab JH, Boland PJ, Agaram NP, Socci ND, Guo T, O'Toole GC, et al. Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother 2009;58:339-49.
16. Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res 1998;58:2417-25. (Pubitemid 28252703)
17. Imai K, Wilson BS, Bigotti A, Natali PG, Ferrone S. A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst 1982;68:761-9.
18. Desai SA, Wang X, Noronha EJ, Zhou Q, Rebmann V, Grosse-Wilde H, et al. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. J Immunol 2000;165:3275-83.
19. Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 1985;5:3610-6. (Pubitemid 16233068)
20. Kusama M, Kageshita T, Chen ZJ, Ferrone S. Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol 1989;143:3844-52. (Pubitemid 20007063)
21. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 2003;62:385-93. (Pubitemid 37338878)
22. Noronha EJ, Wang X, Desai SA, Kageshita T, Ferrone S. Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells. J Immunol 1998;161:2968-76. (Pubitemid 28425721)
23. Sharma S, Tammela J, Wang X, Arnouk H, Driscoll D, Mhawech-Fauceglia P, et al. Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells. Clin Cancer Res 2007;13:5889-96. (Pubitemid 47583916)
24. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, et al. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 1994;13:692-8. (Pubitemid 24050684)
25. de Kruif J, Boel E, Logtenberg T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J Mol Biol 1995;248:97-105.
26. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 1989;8:85-95. (Pubitemid 19082761)
27. Wang X, Campoli M, Ko E, Luo W, Ferrone S. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods 2004;294:23-35. (Pubitemid 39626588)
28. Boulla G, Randriamampita C, Raposo G, Trautmann A. Binding kinetics of soluble ligands to transmembrane proteins: comparing an optical biosensor and dynamic flow cytometry. Cytometry 2000;40:76-80. (Pubitemid 30257278)
29. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006;176:346-56. (Pubitemid 43023280)
30. Stallcup WB, Dahlin K, Healy P. Interaction of the NG2 chondroitin sulfate proteoglycan with type VI collagen. J Cell Biol 1990;111:3177-88. (Pubitemid 120034052)
31. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-8. (Pubitemid 20213280)
32. Ferrone S, Temponi M, Gargiulo D, Scassellati GA, Cavaliere R, Natali PG. Selection and utilization of monoclonal antibody defined melanoma associated antigens for immunoscintigraphy in patients with melanoma. In:Srivastava SC, editor. Radiolabeled monoclonal antibodies for imaging and therapy. NATO ASI Series. Vol 152. New York and London: Plenum Press; 1988. p. 55-73.
33. Buraggi GL, Callegaro L, Mariani G, Turrin A, Cascinelli N, Attili A, et al. Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab′)2 fragments. Cancer Res 1985;45:3378-87. (Pubitemid 15007221)
34. Siccardi AG, Buraggi GL, Natali PG, Scassellati GA, Viale G, Ferrone S. European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group. Eur J Nucl Med 1990;16:317-23. (Pubitemid 20283546)
35. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 2008;68:8066-75.
36. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675-99.
37. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
38. Duksin D, Bornstein P. Changes in surface properties of normal and transformed cells caused by tunicamycin, an inhibitor of protein glycosylation. Proc Natl Acad Sci U S A 1977;74:3433-7. (Pubitemid 8177791)
39. Natali PG, Cavaliere R, Bigotti A, Nicotra MR, Russo C, Ng AK, et al. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol 1983;130:1462-6. (Pubitemid 13159900)
40. Glockshuber R, Malia M, Pfitzinger I, Pluckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 1990;29:1362-7. (Pubitemid 20063361)
41. Huston JS, George AJ, Adams GP, Stafford WF, Jamar F, Tai MS, et al. Single-chain Fv radioimmunotargeting. Q J Nucl Med 1996;40:320-33. (Pubitemid 26370425)
42. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-61. (Pubitemid 18051427)
43. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988;18:1507-14. (Pubitemid 18269332)
44. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993;30:1089-96.
45. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71. (Pubitemid 43939148)
46. Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010;59:1197-209.
47. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5. (Pubitemid 32691886)